



15866 U.S.PTO  
020404

Attorney Docket P1778R1C2  
PATENT

**EV 351 923 206 US: Express Mail Number**

**February 4, 2004: Date of Deposit**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

031356 U.S.PTO  
10/772678  
020404

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**David Y. Jackson,  
Frederick C. Sailes, and  
Daniel P. Sutherlin**

Title: **TYROSINE DERIVATIVES**

**1. Type of Application**

This application is for an original, non-provisional application.

This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.

This is a  continuation-in-part  continuation  divisional application claiming priority under 35 U.S.C. § 120 to U.S. application Serial Number 10/198,328, filed July 16, 2002, which is a continuation of U.S. application Serial Number 09/669,779, filed September 25, 2000, now U.S. Patent No. 6,469,047 B1, which claims priority under 35 U.S.C. § 119 to provisional U.S. application Serial No. 60/156,062, filed September 24, 1999, the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)**

**(Non-provisional )**

72 pages of specification  
10 pages of claims  
1 page(s) of abstract  
0 sheet(s) of drawings  
[] formal    [] informal

**3. Declaration or Oath**

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

(for new and CIP applications)

An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

Cancel in this application original claims \_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**6. Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

| CLAIMS FOR FEE CALCULATION          |    |              |   |            |                             |
|-------------------------------------|----|--------------|---|------------|-----------------------------|
| Number Filed                        |    | Number Extra |   | Rate       | Basic Fee<br>37 CFR 1.16(a) |
|                                     |    |              |   |            | \$770.00                    |
| Total Claims                        | 24 | - 20 =       | 4 | X \$18.00  | \$72.00                     |
| Independent Claims                  | 1  | - 3 =        | 0 | X \$86.00  | \$0.00                      |
| Multiple dependent claim(s), if any |    |              |   | + \$290.00 | \$0.00                      |
| Filing Fee Calculation              |    |              |   |            | \$842.00                    |

**7. Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$842.00. A duplicate copy of this transmittal is enclosed.

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this transmittal is enclosed.

**9. Additional Papers Enclosed**

- [x] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- [x] Other: Limited Recognition Under 37 C.F.R. § 10.9(b)\*

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- X A petition, fee and/or response has been filed to extend the term in the pending prior application until March 2, 2004
- x A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: David W Evans  
Customer No: 09157

Respectfully submitted,  
GENENTECH, INC.

Date: February 4, 2004

By: 

David W Evans  
Reg. No.  
Telephone No. (650) 225-1739

**CUSTOMER NO: 09157**

\* A copy of a document pursuant to 37 CFR §10.9(b) is attached as proof of the authorization of the above to prosecute the referenced application. The original of this document is on file in the Office of Enrollment and Discipline.